China India virus innovations vaccine China India

Covid vaccine maker pharma stocks may zoom as Merkel opposes patent waiver

Reading now: 785
www.livemint.com

Big BusinessVaccines have been a big business for the firms that make them, with Pfizer, BioNTech’s partner outside of China, raising its forecast for 2021 vaccine sales to $26 billion just this week.

Shares of many of the U.S.-listed companies had fallen late in Wednesday’s regular trading session after Tai’s comments.Read more: Analysts say investor fears of U.S.

vaccine waiver support are overblownThe U.S. move “probably isn’t great news for the vaccine manufacturers who will now face generic copies of their vaccine, but as the mutation of the virus has shown, continued research and innovation will be needed and that should provide those companies with future earnings from newer vaccines so I would expect the impact to be short-lived and.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA